$STE

STERIS plc (STE): Submission of Matters to a Vote of Security Holders

STERIS plc (STE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2026 STERIS plc (Exact Name of Registrant as Specified

Original reporting
Published Aug 6, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$STE
Neutral
medium confidence
Mentioned
$STE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The disclosure confirms director elections, auditor ratification/appointment, and renewals of board authority under Irish law. It does not introduce new financial targets, M&A, regulatory findings, or material contract awards.

02

Market read

Routine governance and auditor-related approvals with a board size reduction to nine members; no direct catalyst for fundamentals.

03

What to watch

Traders may watch for any concurrent proxy contest or director-specific concerns, but none are indicated in the disclosed vote tallies.

Relevance 6/10Novelty 3/10Timing: filed after-hours Aug 6, 2026, reflecting July 31 shareholder meeting results

Background

The company submitted Form 8-K Item 5.07 detailing matters voted on at its July 31, 2026 annual general meeting.

Company-level read

Ticker impact

$STENeutralMedium confidence
Context

STERIS filed an 8-K reporting final voting results from its July 31, 2026 annual meeting, including board size reduction to nine.

Expected impact

Likely limited, with any move driven by broader market factors rather than the vote results themselves.

Evidence & confidence

The filing discloses election outcomes, auditor ratification, and renewals of share issuance authorities, but provides no new earnings, guidance, or transaction terms.

Market effects

Minimal. Governance vote outcomes typically do not change sterilization/medical technology demand outlook.

Minimal. US-listed issuer filing, no cross-border policy or macro linkage.

Minimal. No global deal, regulatory action, or product event disclosed.

Counterpoint

Even routine board and auditor items can matter if investors were concerned about governance or audit continuity, but this filing shows standard approvals.

Key entities

  • STERIS plc

    US-listed medical technology company filing the 8-K with final shareholder voting results.

  • Ernst & Young LLP

    Ratified as independent registered public accounting firm for the year ending March 31, 2027.

  • Ernst & Young Chartered Accountants

    Appointed as statutory auditor under Irish law until the next annual general meeting.

Related articles

$STEHighAI 8/10

STERIS Stock Outlook: Is Wall Street Bullish or Bearish?

STERIS plc (STE), a provider of infection prevention products, reported mixed Q2 2026 earnings with revenue of $1.5B, up 7.3% YoY, and adjusted EPS of $2.59, beating estimates. Free cash flow margin declined to 18.7% from 23.5% YoY. Analysts expect EPS to rise 9.1% for the year ending March 2027. The stock has underperformed the S&P 500 and XLV ETF over the past year and 2026. Analysts' consensus is 'Moderate Buy' with a mean price target of $263.75, implying 11.6% upside.

$STEMed

STERIS Q1 Earnings Call Highlights

STERIS (NYSE:STE) reported Q1 Healthcare capital equipment revenue up 1% and ending backlog at $444 million, while capital equipment orders rose 4%. Healthcare EBIT margin increased 60 bps to 24.8%. Life Sciences organic revenue grew 8% and EBIT margin fell to 42.1%. STERIS plans a $600 million North Carolina chemistry center, with FY2027 EPS guidance $11.10 to $11.30.

$STEMed

STERIS Announces Financial Results for Fiscal 2027 First Quarter

STERIS plc (STE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 First Quarter • Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% • Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share i

$STEMedAI 8/10

Are Wall Street Analysts Predicting STERIS Stock Will Climb or Sink?

STERIS plc (STE) has lagged the market, falling 11.2% over the past year versus a 27.9% S&P 500 gain, and is down 14.6% in 2026 YTD. After Q4 results on May 11 (revenue $1.6B, +7.3% YoY; adjusted EPS $2.83, +3.3%), analysts expect FY2027 EPS of $11.18 (+9.9%). Consensus is “Moderate Buy” (5 “Strong Buy,” 3 “Hold”); KeyBanc cut its target to $269.